Thundon Ngamprasertchai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Thundon Ngamprasertchai has a total of 177 co-authors. Here are the top co-authors by number of shared publications:
- Saranath Lawpoolsri
Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
7 shared publications - Viravarn Luvira
Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
7 shared publications - Watcharapong Piyaphanee
Thai Travel Clinic, Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University , Bangkok
6 shared publications - Emi. E. Nakayama
Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita 565-0871, Japan
4 shared publications - Hisham Ahmed Imad
Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
4 shared publications - Pinyo Rattanaumpawan
Mahidol University
4 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 53
Virological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial
- 15 September 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 53
Open AccessVirological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial
- Open Access
- 8 September 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 53
Effectiveness of a trivalent inactivated split-virion influenza vaccine (Tri Fluvac) in Thailand: a phase IV test-negative case-control study
- 8 September 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 53
Open AccessEffectiveness of a trivalent inactivated split-virion influenza vaccine (Tri Fluvac) in Thailand: a phase IV test-negative case-control study
- Open Access
- 27 June 2026
- Published by Elsevier in Value in Health Regional Issues
- Vol. 58, 101663
Japanese Encephalitis Vaccine Preferences and Uptake in Western Travelers and Locals: Strategies to Enhance Vaccine Uptake
- 27 June 2026
- Published by Elsevier in Value in Health Regional Issues
- Vol. 58, 101663
Open AccessJapanese Encephalitis Vaccine Preferences and Uptake in Western Travelers and Locals: Strategies to Enhance Vaccine Uptake
- Open Access
- 30 April 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (6) , 103238
Immunization gaps and measles outbreaks in ASEAN (2015–2025): A systematic review and meta-analysis
- 30 April 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (6) , 103238
Open AccessImmunization gaps and measles outbreaks in ASEAN (2015–2025): A systematic review and meta-analysis
- 18 March 2026
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 33 (4)
Hidden guests: uncovering the microbial reality of hotel environments
Thundon Ngamprasertchai, MD, PhD, Gerard T Flaherty, MD, PhD; Hidden guests: uncovering the microbial reality of hotel environments, Journal of Travel Medi
- 18 March 2026
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 33 (4)
Hidden guests: uncovering the microbial reality of hotel environments
Thundon Ngamprasertchai, MD, PhD, Gerard T Flaherty, MD, PhD; Hidden guests: uncovering the microbial reality of hotel environments, Journal of Travel Medi
- Open Access
- 22 April 2025
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 21 (1) , 2491994
Unveiling the complexity of vaccine hesitancy: A narrative review focusing on dengue vaccination
Dengue vaccines face significant challenges, including safety concerns, which contribute to vaccine hesitancy. Addressing this complex issue requires targeted strategies to overcome existing barriers. Through an extensive review of current evidence, we identified key factors contributing to vaccine hesitancy and explored strategies to enhance global vaccine uptake. Four conceptual models and five assessment tools were identified to understand and measure vaccine hesitancy. Among the factors, "confidence" emerged as the most influential, followed by "complacency." Vaccine acceptance rates varied widely, ranging from 53% to 95%, depending on the region and population. Key determinants included population characteristics, concerns about efficacy and safety, among others. A comprehensive understanding of these factors is essential to improve vaccine acceptance, support dengue prevention efforts, and ensure public health success.
- 22 April 2025
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 21 (1) , 2491994
Open AccessUnveiling the complexity of vaccine hesitancy: A narrative review focusing on dengue vaccination
Dengue vaccines face significant challenges, including safety concerns, which contribute to vaccine hesitancy. Addressing this complex issue requires targeted strategies to overcome existing barriers. Through an extensive review of current evidence, we identified key factors contributing to vaccine hesitancy and explored strategies to enhance global vaccine uptake. Four conceptual models and five assessment tools were identified to understand and measure vaccine hesitancy. Among the factors, "confidence" emerged as the most influential, followed by "complacency." Vaccine acceptance rates varied widely, ranging from 53% to 95%, depending on the region and population. Key determinants included population characteristics, concerns about efficacy and safety, among others. A comprehensive understanding of these factors is essential to improve vaccine acceptance, support dengue prevention efforts, and ensure public health success.
- Open Access
- 31 January 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (2) , ofaf069
Immunogenicity and Safety of the Higher-Valent Pneumococcal Conjugate Vaccine vs the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Background: The immunogenicity of the 15-valent pneumococcal conjugate vaccine (PCV15) and PCV20 in older adults was approved on the basis of comparative data with PCV13, although their relative immunogenicity and safety in this population remain undetermined. A systematic review and meta-analysis were conducted to provide insights, addressing the lack of large-scale efficacy studies. Methods: This analysis included phase 2 and 3 randomized controlled trials evaluating the immunogenicity of a single dose of PCV15 or PCV20 in older adults by opsonophagocytic assay geometric mean titer (GMT) response at 1 month postvaccination as compared with PCV13. Results: In total, 8 trials were eligible. PCV15 demonstrated superior immunogenicity vs PCV13 among older adults (GMT ratio, 1.11; 95% CI, 1.02–1.20). In immunogenicity vs PCV13, PCV20 demonstrated noninferiority, exceeding 0.5 at 1 month postvaccination (GMT ratio, 0.84; 95% CI, .81–.87). The incidence of local and systemic reactions was higher in the PCV15 group as compared with the PCV13 group, with risk ratios of 1.23 (95% CI, 1.14–1.32) and 1.15 (95% CI, 1.02–1.29), respectively. PCV20 is well tolerated and exhibits a comparable rate of local and systemic reactions to PCV13. Conclusions: These findings support the immunogenicity and safety of PCV15 and PCV20 for pneumococcal vaccination in older adults. Given its superior immune response, PCV15 may address the gaps left by PCV13. Despite higher antibody levels, the clinical effectiveness of these vaccines remains uncertain. Ongoing surveillances are essential to evaluate the impact of both vaccines on remaining vaccine-type pneumococcal disease.
- 31 January 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (2) , ofaf069
Open AccessImmunogenicity and Safety of the Higher-Valent Pneumococcal Conjugate Vaccine vs the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Background: The immunogenicity of the 15-valent pneumococcal conjugate vaccine (PCV15) and PCV20 in older adults was approved on the basis of comparative data with PCV13, although their relative immunogenicity and safety in this population remain undetermined. A systematic review and meta-analysis were conducted to provide insights, addressing the lack of large-scale efficacy studies. Methods: This analysis included phase 2 and 3 randomized controlled trials evaluating the immunogenicity of a single dose of PCV15 or PCV20 in older adults by opsonophagocytic assay geometric mean titer (GMT) response at 1 month postvaccination as compared with PCV13. Results: In total, 8 trials were eligible. PCV15 demonstrated superior immunogenicity vs PCV13 among older adults (GMT ratio, 1.11; 95% CI, 1.02–1.20). In immunogenicity vs PCV13, PCV20 demonstrated noninferiority, exceeding 0.5 at 1 month postvaccination (GMT ratio, 0.84; 95% CI, .81–.87). The incidence of local and systemic reactions was higher in the PCV15 group as compared with the PCV13 group, with risk ratios of 1.23 (95% CI, 1.14–1.32) and 1.15 (95% CI, 1.02–1.29), respectively. PCV20 is well tolerated and exhibits a comparable rate of local and systemic reactions to PCV13. Conclusions: These findings support the immunogenicity and safety of PCV15 and PCV20 for pneumococcal vaccination in older adults. Given its superior immune response, PCV15 may address the gaps left by PCV13. Despite higher antibody levels, the clinical effectiveness of these vaccines remains uncertain. Ongoing surveillances are essential to evaluate the impact of both vaccines on remaining vaccine-type pneumococcal disease.
- Open Access
- 21 December 2024
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 32, 100523
Unveiling immunity gaps and determining a suitable age for a third dose of the measles-containing vaccine: a strategic approach to accelerating measles elimination
- 21 December 2024
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 32, 100523
Open AccessUnveiling immunity gaps and determining a suitable age for a third dose of the measles-containing vaccine: a strategic approach to accelerating measles elimination
- Open Access
- 11 September 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (10) , ofae520
Evaluating Antibiotic Misuse and Cost Analysis Among Hospitalized Dengue Virus–Infected Adults: Insights From a Retrospective Cohort Study
Background: Dengue is a prevalent cause of acute febrile illness, predominantly in Asia, where it necessitates supportive care without the need for antibiotics. This study aimed to evaluate antibiotic usage and analyze hospitalization costs among adults infected with the dengue virus. Methods: This retrospective cohort study was conducted at the Hospital for Tropical Diseases, Thailand, in 2022. Two independent reviewers assessed all adult cases with confirmed dengue from 2016 to 2021. Determinants of inappropriateness were analyzed using Poisson regression. Results: The study included 249 participants with over half presenting with severe dengue or dengue with warning signs upon admission. The cumulative incidence of antibiotic use was 9.3% (95% CI, 8.23–10.47), predominantly involving empirical treatment strategies. Ceftriaxone and doxycycline were the most frequently prescribed antibiotics. Notably, patients who received empirical antibiotics showed no definite or presumed bacterial infections. Among those who received definite strategies, inappropriate durations, including both short treatments and the overuse of broad-spectrum antibiotics, were observed. A private ward admission was identified as a significant predictor of inappropriate use, with an incidence rate ratio of 4.15 (95% CI, 1.16–14.82) compared with intensive care unit admission. Direct medical costs did not differ significantly between appropriate and inappropriate uses. Conclusions: The incidence of antibiotic use among dengue cases was moderate; however, inappropriate use by indication was observed. Antimicrobial stewardship strategies should be encouraged, particularly in patients with dengue with warning signs admitted to a general or private ward. Direct medical costs between appropriate and inappropriate use were comparable.
- 11 September 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (10) , ofae520
Open AccessEvaluating Antibiotic Misuse and Cost Analysis Among Hospitalized Dengue Virus–Infected Adults: Insights From a Retrospective Cohort Study
Background: Dengue is a prevalent cause of acute febrile illness, predominantly in Asia, where it necessitates supportive care without the need for antibiotics. This study aimed to evaluate antibiotic usage and analyze hospitalization costs among adults infected with the dengue virus. Methods: This retrospective cohort study was conducted at the Hospital for Tropical Diseases, Thailand, in 2022. Two independent reviewers assessed all adult cases with confirmed dengue from 2016 to 2021. Determinants of inappropriateness were analyzed using Poisson regression. Results: The study included 249 participants with over half presenting with severe dengue or dengue with warning signs upon admission. The cumulative incidence of antibiotic use was 9.3% (95% CI, 8.23–10.47), predominantly involving empirical treatment strategies. Ceftriaxone and doxycycline were the most frequently prescribed antibiotics. Notably, patients who received empirical antibiotics showed no definite or presumed bacterial infections. Among those who received definite strategies, inappropriate durations, including both short treatments and the overuse of broad-spectrum antibiotics, were observed. A private ward admission was identified as a significant predictor of inappropriate use, with an incidence rate ratio of 4.15 (95% CI, 1.16–14.82) compared with intensive care unit admission. Direct medical costs did not differ significantly between appropriate and inappropriate uses. Conclusions: The incidence of antibiotic use among dengue cases was moderate; however, inappropriate use by indication was observed. Antimicrobial stewardship strategies should be encouraged, particularly in patients with dengue with warning signs admitted to a general or private ward. Direct medical costs between appropriate and inappropriate use were comparable.
- Open Access
- 29 August 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 148, 107226
Prevalence of dengue, Zika, and chikungunya virus infections among mosquitoes in Asia: A systematic review and meta-analysis
- 29 August 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 148, 107226
Open AccessPrevalence of dengue, Zika, and chikungunya virus infections among mosquitoes in Asia: A systematic review and meta-analysis